Explain the difference between an AI PM at a model lab and one at an application company.

Helicon Genomics builds a model that reads a patient's DNA and calls out where it differs from a reference genome, the first step toward finding a cancer driving mutation. Stillmarsh Diagnostics licenses that same model to read real tumor biopsies and hand oncologists a call they can act on. Edvard Kesling runs the AI PM job at Helicon. Suraya Nazir runs it at Stillmarsh. Same model. Two very different jobs, and for months nobody noticed how differently the two of them were actually being measured.

How to answer this, stage by stage

Nobody is grading whether you can name two job titles. They are grading whether you can hold a benchmark and a real patient's bottleneck apart, out loud, without letting either one quietly stand in for the other.

Let's learn

The artifact is a two page report, read down a phone line to an oncologist who has a treatment decision to make this week.

A DNA sequencer reads a patient's tumor sample and breaks it into millions of short fragments of code, called reads. A variant caller lines those reads up against a reference genome and decides where the patient's DNA is actually different, a possible cancer driving mutation. These days, that lining up and deciding is usually done by a trained model.

Five steps. The middle one, deciding where the DNA is actually different, is the step this whole answer turns on.

Stillmarsh ran on Helicon's older checkpoint, v2.1. Suraya's lab watched one number every week: the false call rate on real biopsies, mutations flagged as real that turned out, on a closer look, not to be there. It held at 1.8 percent. Manageable. About one flagged mutation in fifty six went to a confirmatory retest, and oncologists trusted the calls that came back.

Same model, two different customers. Neither one is wrong about what to optimize for, in their own job.

Then Helicon shipped v3. On GIAB, its F1 score, a single number combining how many real mutations it catches and how many of its calls are actually real, climbed from 98.7 to 99.4. Nine other labs cited it and built it into their own pipelines within the year.

Suraya's team saw the benchmark jump and did what a written policy told them to do: any checkpoint that beats the last one on Helicon's published number gets promoted to production within two release cycles. No new validation run against Stillmarsh's own samples first. Months later, a retrospective audit found the false call rate on real biopsies had climbed to 5.1 percent.

What it costs at its worst: real patients were flagged for actionable mutations that were not there. Some got sent back for a second, invasive biopsy. One oncologist started quietly re-checking Stillmarsh's calls against an outside lab before trusting them, which erased the entire reason Stillmarsh's report existed in the first place, to be the one call a doctor did not have to double check.

What I would leave alone: Stillmarsh also runs the same pipeline on fresh frozen research samples for a biobank partner, not tumor biopsies preserved in wax. Those samples look almost exactly like GIAB. Their accuracy improved right alongside Helicon's benchmark, and nothing about this problem touches that pipeline. It works exactly the way a benchmark win should.

The lesson: a benchmark score is a claim about the sample it was measured on. It was never a claim about yours. Every time a number gets adopted without asking whose sample it was measured against, the cost shows up somewhere else, later, quieter, on somebody who never saw the leaderboard.

Now here is the same thing as a story

The short version above is what you actually say out loud. Read this one for the months that actually got Edvard and Suraya here, and the one question that finally cracked it open.

For six years, Edvard Kesling's job was to make a number go up. For six months, Suraya Nazir's job was to make sure that number never quietly hurt someone.

Edvard runs model research at Helicon Genomics, four floors of sequencers and GPU racks converted out of an old textile mill. His team's whole world is GIAB: seven reference genomes, sequenced so many times by so many labs that the truth is basically settled. Beat last year's F1 score on those seven genomes, and the model ships a paper, gets a release number, and Edvard's job is done.

Suraya runs product at Stillmarsh Diagnostics, forty miles away, where a lab technician loads a real patient's tumor sample onto a sequencer every morning by eight. Her job has no leaderboard. It has an oncologist on the other end of a phone, deciding, off Stillmarsh's report, whether to start a targeted drug or order more tests.

Nobody decided, on any single day, to skip checking v3 against Stillmarsh's own samples. A policy written eighteen months earlier just never asked anyone to.

When Helicon shipped v3, Edvard's team had genuinely earned the number: 99.4 on GIAB, up from 98.7, the kind of gain that used to take two years and now took eight months. Nine labs built it into their own pipelines by the following spring. Everyone at Helicon called it a good year.

Stillmarsh's own policy did the rest without anyone deciding anything in the moment. Any checkpoint that beat the last one on Helicon's published benchmark got promoted to production within two release cycles. It had been written eighteen months earlier, back when Stillmarsh's own samples and GIAB were close enough that the shortcut never cost anything. v3 went live on a Tuesday. Nobody ran a new validation pass against Stillmarsh's own archive of real biopsies first, because the policy never asked them to.

For three months, nothing looked wrong. The lab kept running its usual weekly count of confirmatory retests, and the number crept, not jumped, from 1.8 to 2.4, then 3.6 percent. Creeping is easy to miss. A jump gets a meeting. A creep gets absorbed into "some weeks are just noisier than others."

The whole story in one picture. One model, tested on two benches, and only one of them looks anything like Stillmarsh's actual patients.

Then, in week fourteen, a pathologist who had joined Stillmarsh two months earlier pulled a report on a lung tumor and stopped. The report flagged a mutation with no business showing up in that tissue type, ever, in anyone's experience. She had not been at Stillmarsh long enough to know the number everyone else had quietly stopped watching. She just asked Suraya a question nobody could answer on the spot: "Has anyone actually re-run our own samples through v3, or did we just trust the benchmark?"

The retrospective audit that followed took three weeks and pulled four hundred and twenty archived biopsies back through the pipeline. The false call rate on real samples: 5.1 percent, nearly three times where it stood before v3. Every one of those extra false calls traced back to the same known chemistry problem, wax preserved DNA looking, in exactly the wrong spot, like a real mutation. GIAB, built from close to perfect DNA, had never once contained a sample with that damage in it. There was nothing for the benchmark to fail on. It simply never got asked the question.

The decision Suraya would take back sits in a policy document from eighteen months earlier, written back when a fast checkpoint promotion felt like keeping pace with the field, not a risk anyone was taking. Nobody ever came back to ask whether the shortcut still fit a lab running real patient samples instead of a research pipeline.

Run the same six months again, with one gate added: any new checkpoint has to clear Stillmarsh's own four hundred archived biopsies before it goes live, not just Helicon's seven reference genomes. v3 still ships. It still scores 99.4 on GIAB. But on Stillmarsh's own gate, its false call rate comes back at 4.8 percent against v2.1's 1.8, and the promotion stops right there, three months and one pathologist's question earlier than it actually did, before a single real patient's report ever carried a mutation that was never there.

What Suraya would tell herself, back when that policy first got written: chasing the field's pace was never the mistake. Trusting somebody else's test to speak for her own patients, that was.

Same checkpoint, two jobs: PICK, letter by letter

Not a way to decide whose job is harder. PICK is what forces you to say, out loud, which kind of wrong you can afford loud, and which one you cannot afford quiet.

One mistake sits on a shelf where everyone can see it doing nothing. The other one hides inside a report that looks, on the surface, like it went fine.

Three things worth saying directly, since this is where the real judgment sits. Suraya's team considered a narrower fix instead of a full revalidation gate: just raise the confidence bar for calling a mutation "likely pathogenic," so fewer borderline calls got reported at all. It lost, because raising the bar blindly would have traded false calls for missed real mutations on the exact same messy data, without ever touching why the artifacts were showing up in the first place. The AI specific failure worth naming by name is a benchmark that cannot see the failure mode that matters: GIAB is built from clean, undamaged DNA, so a wax preservation artifact common in real tumor tissue never once appears in it, no matter how high the score climbs. The guardrail is the revalidation gate itself, checked against Stillmarsh's own archived biopsies before every promotion, not a note in a release email that assumes the benchmark speaks for everyone. And the trade off is real and accepted on purpose: that gate adds three to four weeks to every checkpoint adoption, which means Stillmarsh always runs one version behind Helicon's newest release, a deliberate lag traded for not finding out the hard way.

And if you want to be sure it really works, try it somewhere else

Same four letters, a farm field instead of a hospital lab, and this time the thing nobody separates is a studio-quality leaf photo from a leaf a farmer actually has to walk past at dusk, dusty and half in shadow.

Verdigris Vision Lab builds a model that spots early blight on crop leaves from a photo, benchmarked on a curated set of leaf images, clean, well lit, one leaf centered per shot. Rootline Ag licenses that same model and runs it on real field cameras mounted on tractors, where every photo has dust, uneven light, and leaves overlapping each other. Salvatore Melling runs the AI PM job at Verdigris. Anastazia Prochnow runs it at Rootline, and faced the same choice Suraya did: adopt the newest checkpoint because the leaderboard says to, or check it against her own conditions first.

Same shape of pipeline as the biopsy one. The step that breaks is still the model, and still for the same reason: a benchmark that never saw the real conditions.

Verdigris's early blight detection accuracy on its curated leaf photo benchmark climbed from 94.1 to 98.3 percent. Rootline's own false negative rate, missed blight cases on real field photos, held at 12 percent before the switch. After adopting the new checkpoint the same week the leaderboard update posted, without revalidating against Rootline's own field photos, missed cases rose to 27 percent, because the newer model had been tuned on crisp, centered leaf images and turned out far less tolerant of blur and dust than the version it replaced.

Mapped straight onto PICK: the position is the same shape, Salvatore's customer is the leaderboard, Anastazia's customer is a farmer deciding whether to spray tonight. The impact splits the same way too, a benchmark win that never becomes usable costs Verdigris a slow quarter; a checkpoint promoted on that win alone costs Rootline missed blight windows that spread before anyone notices. The cost asymmetry lands identically: holding a new checkpoint back until it clears Rootline's own field photo set is cheap and visible, a short delay everyone can see the reason for; promoting on the benchmark alone is hidden and expensive, a missed disease window that only shows up as a bigger spray bill three weeks later. And the kill criteria transfer directly: the moment Rootline's own field set starts moving with the benchmark instead of against it, the delay stops earning its cost.

Swap the trigger and it still runs.
Speed: an interviewer caps you at ninety seconds. Skip straight to it: hold every new checkpoint at the applied product until it clears the applied team's own real-sample set, no matter how good the benchmark looks.
Cost: no budget for a dedicated revalidation pipeline this quarter. Ship the checkpoint, but require the applied team to sign off in writing that they ran it against a sample of their own real data first, free, before anyone else touches production.
The model got better, for real: say Helicon's next release reaches 99.8 on GIAB. Still gate it. A cleaner benchmark and a messier real sample are two different distributions, and "better" on one says nothing on its own about the other.

Where people run it wrong.
They treat any benchmark win as an automatic product win, without asking whose data the win was measured on.
They let a model lab's own promise about capability substitute for the applied team's own validation.
They fix the gap after a real failure instead of writing the revalidation gate down before anyone needs it.

How to use it live. Before answering, ask yourself one thing: whose data was this number actually measured against, and is that the same data your own product runs on. If you cannot answer that in one sentence, you have not actually separated the two jobs yet, you have just renamed one of them.

Flashcards (tap any card to flip it)

Check yourself Score: 0 / 0